Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chongqing Medicine》 2017-26
Add to Favorite Get Latest Update

Targeting effect of TLS9a nucleic acid aptamer on mice hepatic cancer cells

Wei Liping;Wang Dujin;Zou Tiantian;Fei Anxing;Department of Clinical Laboratory,Tuanchengshan Branch Hospital,Huangshi Municipal Maternal and Child Health Care Hospital;Department of Clinical Laboratory,Huangshi Municipal Central Hospital;  
Objective To investigate the targeting effect of TLS9 anucleic acid aptamer on mice hepatic cancer cells.Methods The liposome modified with maleimide and loading doxorubicin(DOX)was prepared,then TLS9 anucleic acid aptamer modified by FITC fluorescence and sulfydryl was synthesized,which was coupled to the liposome surface.The entrapment efficiency of DOX was detected by UV spectrophotometry.The dynamic light scattering(DLS)was applied to measure the particle size of nanoparticles and the potential distribution.The uptake of DOX in mice hepatic cancer cells was detected by the Nikon inverted microscope and the mean fluorescence intensity of liposome/DOX and TLS9a-liposome/DOX was detected by flow cytometry.The cells activity was detected by MTT.Results Flow cytometry assay showed that the binding rate of TLS9 anucleic acid aptamer with BNL.1ME.A.7R.1mice hepatic cancer cells was 54.1%.TLS9a-liposome particle size distribution was in(116.0±5.0)nm.TLS9a-liposome/DOX released DOX quickly at pH 5.0,and the release amount in 72 hwas more than 70% of the total release amount.TLS9a-liposome/DOX effectively inhibited the growth of mice hepatic cancer cells BNL.1ME.A.7R.1.Conclusion TLS9 anucleic acid aptamer could specifically combined with mice hepatic cancer cells BNL.1ME.A.7R.1,which could be used to detect mice hepatic cancer cells.
【CateGory Index】: R735.7
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved